Synopsis Valsartan competitively and selectively inhibits the actions of angiotensin II at the
AT 1 receptor subtype which is responsible for most of the known effects of angiotensin II. In …

Objective: To compare the antihypertensive efficacy and systemic tolerability of valsartan, a
new angiotensin II receptor antagonist, with placebo and with an angiotensin converting …

Objective: To compare the efficacy, safety and tolerability of valsartan to an angiotensin-
converting enzyme (ACE) inhibitor, lisinopril, and placebo in patients with mild-to-moderate …

We compared the angiotensin II receptor antagonist valsartan to losartan as an
antihypertensive agent in an 8-week trial. Adults with uncomplicated essential hypertension …

Objective: The pharmacokinetics of orally and intravenously administered valsartan were
determined in two studies. In a first pilot study, three iv doses of valsartan were given in an …

A multicenter, randomized, placebo-controlled, double-masked, parallel-group study was
performed to compare the efficacy and safety of valsartan 20, 80, 160, and 320 mg with …

Objective To compare the antihypertensive efficacy of a new angiotensin II antagonist,
valsartan, with a reference therapy, amlodipine. Methods One hundred sixty‐eight adult …

Objective: Pharmacokinetics, pharmacodynamic effects and tolerability of 200 mg valsartan,
once-daily for 8 days, were investigated in 16 healthy, normotensive volunteers on a normal …

This report presents data on the safely and tolerabilify of losartan potassium (losartan), a
selective antagonist of the angiotensin II AT-1 receptor, in approximately 2,900 hypertensive …

Abstract Valsartan (CGP 48933), a specific blocker of the angiotensin II (Ang II) receptor
subtype 1 (AT 1 receptor) was administered in single, oral doses of 40 mg and 80 mg to six …